U.S. Compounding Pharmacies Market Revenue to Attain USD 10.34 Bn by 2033

21 Mar 2025

Share :

Table of Content

1. U.S. Compounding Pharmacies Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Report Highlights 4. Market Trends 5. Market News 6. U.S. Compounding Pharmacies Market Key Players 7. Market Segmentation

U.S. Compounding Pharmacies Market Revenue and Trends 2025 to 2033

The global U.S. compounding pharmacies market revenue was valued at USD 6.45 billion in 2025 and is expected to attain around USD 10.34 billion by 2033, growing at a CAGR of 10.93% during forecast period. The demand for advanced research and development facilities is increasing, which is the key factor driving the growth of the market.

Market Overview

The U.S. compounding pharmacies market covers a range of community-based pharmacies and experts in the preparation of non-sterile and sterile medications in the U.S. These customized formulations are tailored to patients with different requirements, like allergies to specific medication strengths and inactive ingredients. The market is characterized between 503A and 503B compounding pharmacies, emphasizing patient-specific, small-scale prescriptions to produce larger batches of sterile formulations.

Report Highlights

• By product, the oral segment held the largest U.S. compounding pharmacies market share in 2024. The dominance of the segment can be attributed to the increasing incidence of chronic diseases across the globe. The liquid preparations segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be credited to the liquid pharmaceuticals giving more pleasant formulations than other ones.
• By pharmacy type, the 503A segment dominated the market in 2024. The dominance of the segment can be linked to the increasing need for medicine prescriptions and government regulations on drug production. The 503B segment is anticipated to grow at the fastest rate over the forecast period. The growth is due to the stringent regulations for biannual monitoring and audit.
• By sterility, the non-sterile segment led the market in 2024. The dominance of the segment is owing to the increasing incidence of chronic diseases across the globe. The sterility segment is expected to grow at the fastest rate over the period studied. The growth of the segment is because of the increasing need for sterile compounding pharmacies in the medical sector.
• By therapeutic area, the hormone replacement segment dominated the market owing to the rising prevalence of all types of cancer among the majority of the population in the world. The pain management segment is projected to grow at the fastest rate during the forecast period. The growth of the segment is credited to the increasing adoption of painkillers by patients suffering from various disease ailments.

Market Trends

Increasing Acceptance of Bioidentical Hormone Replacement Therapy

A surge in general awareness regarding the benefits of individualized hormone treatments is anticipated to boost the U.S. compounding pharmacies market. The increase in awareness and acceptance of hormone replacement therapy (HRT) is the latest trend in the market. Also, many women, especially those in menopause, are shifting towards bioidentical hormones, which are similar to naturally produced hormones and more convenient and safer than synthetic hormones.

• Advancements in Technology

The U.S. compounding pharmacies market is witnessing some advanced trends with a surge in the rollout of innovative technologies meant to improve the efficiency and accuracy of compounded medications. Moreover, in recent years, there have been many substantial innovations, such as the automated compounding system, which is used for mixing and preparing formulations very accurately, giving a minimum chance for human error.

• Regulatory Compliance for Compounding Pharmacies

Regulatory changes that optimize personalized drug preparations and shift towards patient-centric care are propelling the market growth soon. Furthermore, compounding pharmacies play an essential role in enhancing drug adherence by providing medications in forms that are convenient for patients to take, like modified or flavored dosages, improving positive market growth.

Country Insights

The increasing investments by major players in the U.S. compounding pharmacies market in R&D to customize and innovate the formulations to efficiently treat many disorders are anticipated to propel the growth of the market. Furthermore, regulatory innovations supporting personalized drug formulations coupled with the increasing inclination towards patient-centric care are further fueling the market growth in the region. Also, the lack of commercial availability of drugs and innovations in pharmaceutical compounding technologies can impact positive regional expansion. The major market players in the country include Triangle Compounding Pharmacy, B. Braun Melsungen Ag, U.S. Compounding Inc., Vertisis Custom Pharmacy, and Avella Specialty Pharmacy.

Market News

• In April 2024, Myonex acquired Safeway Compounding Pharmacy to enhance its portfolio and strengthen its position in the customized medication market. This acquisition aims to expand Myonex's service capabilities and market reach.
• In October 2024, Novo Nordisk opened a new tab and asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely. U.S. regulations allow compounders to copy brand-name medicines that are in short supply by combining, mixing, or altering drug ingredients to meet demand.
• In April 2024, Myonex, a global clinical trial supply company, announced that it had completed its acquisition of Safeway Compounding Pharmacy.1 This move will allow Myonex to better supply patients in clinical trials with medication and equipment as needed. It will also help the company expand its clinical trial designs and include direct-to-patient and home healthcare provider capabilities.
• In May 2023, Fresenius Kabi launched Diazepam Injection, USP in 10 mg per 2 mL Simplist prefilled syringes, available in the U.S. This new addition to the Simplist portfolio aims to streamline medication delivery and reduce the risk of errors with its ready-to-administer design.

U.S. Compounding Pharmacies Market Key Players

• Triangle compounding pharmacy
• Fagron
• B. Braun melsungen ag
• Fresenius kabi ag
• Pencol Compounding Pharmacy
• US Compounding Inc.
• Avella specialty pharmacy
• Institutional pharmacy solutions, llc
• Pharmedium services llc
• Vertisis custom pharmacy

Market Segmentation

By Pharmacy Type

• 503A
• 503B

By Product

• • Oral
  • Capsules
  • Granules
  • Tablets
  • Powder
  • Others
• Liquid Preparations
  
  • Emulsion
  • Syrup
  • Solutions
  • Suspension
  • Others
• Topical
  
  • Gels
  • Ointments
  • Creams
  • Pastes
  • Others
• Rectal
  
  • Enema
  • Suppositories
  • Others
  • Ophthalmic
  • Nasal
  • Otic

By Sterility

• Sterile
• Non-Sterile

By Compounding Type

• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)
• Others

By Therapeutic Area

• Hormone Replacement
• Pain Management
• Dermatology
• Pediatrics
• Urology
• Others

By End-User

• Hospitals and Clinics
• Specialty Clinics
• Others

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/sample/1662

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344